These data suggests that the role of mTOR is very different depending on the timing/disease stage since rapamycin treatment during allergen re-exposure or during chronic, ongoing disease did not attenuate key characteristics of allergic asthma including AHR and inflammation and actually augmented IL-4 and eotaxin 1 levels. The gene discussed is MTOR; the disease is allergic asthma.